Company news
Hutchmed (china) Limited (HKEX:13) news
Hutchmed (china) Limited news releases on 6ix. Latest, Oct 2, 2026: Monthly Return of Equity Issuer on Movements in Securities for the month ended September…
Press releases & updates
Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2026
October 2, 2026
VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer
September 28, 2026
VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
September 27, 2026
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
September 27, 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 2, 2026
HUTCHMED Reports 2026 Interim Results
July 30, 2026
HUTCHMED to Announce 2026 Half-Year Financial Results
June 30, 2026
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 21, 2026
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026